x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

DarshanTalks Podcast

Darshan Kulkarni

Welcome to DarshanTalks!We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.We focus on life science issues involving

science life sciences

All Episodes

1:01

What Does ICH E6 R3 Say About Returning Data to...

DarshanTalks Podcast ·

2025/02/05

The most recent ICH E6(R3) final guidance introduces critical updates to Good Clinical Practice (GCP), particularly around informed consent and participant data access. The guidance emphasizes greater flexibility and the use of technology-driven innovations to enhance how patients understand what they are consenting to. A significant update appears in section 2.8 (Investigator Responsibilities), which now requires a clear plan for returning trial-related data to participants when appropriate....

en-us

2:28

Navigating the Ongoing HHS Communication Freeze

DarshanTalks Podcast ·

2025/02/04

Now that we’ve passed February 1st, a key date for the potential easing of the freeze on all HHS communications, we find ourselves at February 3rd with no significant updates or changes. Despite expectations that restrictions might begin to lift, there has been no broad release of communications across federal agencies involved in clinical trials and regulatory oversight. While this does not provide definitive insight into the administration’s plans, it does confirm that, for now, the freeze ...

en-us

3:47

Ordinary People Are Changing Medicine

DarshanTalks Podcast ·

2025/02/03

Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medicine falls short. Driven by necessity, love, and a desire for survival, many have solved complex medical problems themselves, leading to groundbreaking discoveries. This trend raises important questions about safety, ethics, and the future of healthcare, with both promise and complexity. One of the most well-known examples is Lorenzo’s Oil, where ...

en-us

2:29

Trump’s First 10 Days: The Impact on Clinical Trials

DarshanTalks Podcast ·

2025/01/31

Edye Edens discusses how the first nine to ten days under the new administration have brought notable shifts for both healthcare and clinical research, particularly in regulatory compliance and funding. While remaining politically neutral, the focus is on understanding how these changes impact clinical trials and research oversight. A key update is that the federal communication freeze across health agencies is expected to ease by February 1, which should provide more clarity on the administr...

en-us

0:58

Selling a Business with Issues

DarshanTalks Podcast ·

2025/01/31

When selling a company, certain issues may arise that could concern potential buyers. Here's a breakdown of how to approach them:Price Adjustments: Some issues can be acknowledged, and the buyer may adjust the price accordingly, allowing the sale to proceed with minimal adjustments.Successor Liability: Issues like DOJ concerns or successor liability might require more attention, especially in asset-based transactions.Risk-Based Analysis: For less critical matters, such as design defects, you ...

en-us

11:44

Breaking Down GCP E6(R3)

DarshanTalks Podcast ·

2025/01/28

Darshan Kulkarni and Edye Edens discuss the latest update to Good Clinical Practice (GCP) guidelines, E6 R3, was explored. GCP, developed by the International Council for Harmonisation (ICH), provides globally accepted ethical and operational standards for conducting clinical trials. The 2025 update represents a significant revision since its last update in 2016, emphasizing technology, data integrity, and structural changes to accommodate rapid innovation in clinical research.Key Highlights ...

en-us

5:54

AdvaMed 7 rules for Essential AI Innovation

DarshanTalks Podcast ·

2025/01/25

Artificial intelligence (AI) is rapidly reshaping healthcare, with over 950 FDA-authorized AI devices transforming diagnosis, treatment, and administrative workflows. AdvaMed's new position paper emphasizes seven foundational principles to guide AI in medical technology development and regulation.Key Highlights:A Robust Regulatory Framework: AdvaMed urges alignment with international standards for AI-driven innovations while maintaining patient safety.Privacy and Data Transparency: Transparen...

en-us

1:21

Teva’s Case Should Shape Your Pharma Strategy

DarshanTalks Podcast ·

2025/01/22

Teva Pharmaceutical's $450 million settlement highlights the challenges of compliance in the pharmaceutical industry. The Department of Justice accused Teva of violating the anti-kickback statute and the False Claims Act by using co-payment assistance programs to steer Medicare payments for its drug Copaxone while raising prices. Additionally, Teva admitted to price-fixing schemes for generic drugs like pravastatin. This case serves as a stark reminder that compliance isn't just about avoidin...

en-us

8:10

🔒 AI’s Impact on Healthcare: Liability, Ethics, and...

DarshanTalks Podcast ·

2025/01/21

Subscriber-only episodeToday, we explore a pressing issue in the healthcare landscape: the liability associated with artificial intelligence (AI). As AI technologies transform healthcare—from diagnostic tools to treatment recommendations—it's crucial to understand the legal and ethical implications surrounding their use, particularly regarding accountability.AI systems can analyze vast amounts of data, providing insights that aid in diagnosing diseases and personalizing treatment plans. Howev...

en-us

4:56

Four Types of Research related Grant Fraud

DarshanTalks Podcast ·

2025/01/18

Grant fraud encompasses four critical issues that can have severe repercussions for institutions and individuals.1. Foreign Influence and Funding:Failing to disclose foreign government support, as seen in Ohio State University's $875,000 settlement (November 2022).Similar allegations against U Ming Qing Xiao in the Southern District of Illinois (April 2022).2. Misrepresenting Data for Funding:Using falsified or fabricated data to secure grants undermines the integrity of funding decisions.The...

en-us

0:53

Defining Scope in Due Diligence Transactions

DarshanTalks Podcast ·

2025/01/17

When conducting due diligence for a life sciences company, it's essential to align the scope with the transaction's objectives. Key considerations include:Transaction Purpose: Determine if the goal is asset divestiture, strategic acquisition, or another objective.Regulatory Compliance: Assess adherence to industry regulations, including FDA guidelines and privacy laws.Operational Areas: Evaluate critical functions such as sales, marketing, and manufacturing processes.Risk Assessment: Identify...

en-us

7:33

Clinical Trial Checklist

DarshanTalks Podcast ·

2025/01/16

Darshan Kulkarni and Edye Edens discuss the essential steps for launching a clinical trial site, emphasizing the importance of navigating both state-specific regulations and the logistics involved. They begin by highlighting the critical role of informed consent and legal authority, which vary across states. In particular, states like Texas and California have stringent regulations that can impact how clinical research organizations are structured, especially regarding ownership and the corpo...

en-us

11:28

Presidential Changes and Impact on Drug Related...

DarshanTalks Podcast ·

2025/01/14

Misinformation around vaccines and treatments isn’t new, but with figures like Robert F. Kennedy Jr. in the spotlight, how should regulatory agencies respond?There will be potential changes coming to the FDA and public health regulations with the new administration. Historical transitions, such as the one from the Obama administration to the Trump administration, will shape policy going forward, particularly in terms of regulatory priorities. The government will need to combat misinforma...

en-us

4:10

Prep for Selling Your Company!

DarshanTalks Podcast ·

2025/01/12

When preparing to sell your pharmaceutical company, particularly with a Phase 1 product, it’s essential to assess potential buyers and ensure readiness. Darshan’s Insights: When preparing to sell your pharmaceutical company, it’s crucial to evaluate potential buyers and readiness. Key factors include:1. Compliance Programs:Ensure adherence to OIG rules and updated compliance elements.DOJ expectations require established compliance programs, privacy policies, and Sunshine Act adheren...

en-us

6:00

Top Tips for Starting a Clinical Trial Site

DarshanTalks Podcast ·

2025/01/10

Launching a clinical trial site is an exciting opportunity, but it comes with important legal, regulatory, and operational challenges.Darshan Kulkarni Says: Starting a clinical trial site is an exciting step, but it requires careful planning to address key legal and regulatory considerations. Privacy compliance is a major factor—going beyond HIPAA to account for email and text marketing laws, state-specific business registrations, and corporate structures like MSOs to manage ownership ru...

en-us

4:27

When Drug Reps Visit: Darshan Reacts

DarshanTalks Podcast ·

2025/01/09

Darshan reacts to a fake interaction between a drug sales representative and a doctor. He shares insights on pharmaceutical marketing tactics, highlighting that while doctors often find sales reps personable, they may not trust them as much as medical science liaisons (MSLs) due to limitations on what reps can legally discuss about drugs. Darshan explains industry regulations, such as the Pharma Code and the Sunshine Act, which restrict certain gifts to avoid conflicts of interest. He also cr...

en-us

2:29

Is Pfizer competing with your pharmacy?

DarshanTalks Podcast ·

2025/01/08

Pharmaceutical companies, like Pfizer, are venturing into digital healthcare platforms, raising questions about competition with traditional pharmacies. Pfizer recently announced its initiative, "Pfizer for All," a digital platform that offers services such as vaccine scheduling and potential savings on medications, possibly bypassing pharmacy benefit managers (PBMs). This platform supports patients with private and government insurance, but there are concerns about how it addresses those wit...

en-us

23:54

Talking to a Functional Medicine Doctor

DarshanTalks Podcast ·

2025/01/07

In this episode, guest host Kate Woods interviews Jessica Miller, who shares her journey with functional medicine, highlighting its focus on addressing root causes of illness through personalized, lifestyle-based approaches. They discuss its challenges, benefits, and empowering patients to take charge of their health.Functional medicine focuses on addressing the root causes of illness and disease rather than simply treating symptoms, which is often the approach in traditional Western medicine...

en-us

4:56

Four Types of Research related Grant Fraud

DarshanTalks Podcast ·

2025/01/05

Grant fraud encompasses four critical issues that can have severe repercussions for institutions and individuals:Foreign Influence and Funding:Failing to disclose foreign government support, as seen in Ohio State University's $875,000 settlement (November 2022).Similar allegations against U Ming Qing Xiao in the Southern District of Illinois (April 2022).Misrepresenting Data for Funding:Using falsified or fabricated data to secure grants undermines the integrity of funding decisions.The DOJ a...

en-us

5:17

🔒 Leveraging AI and RWD to Reshape Drug Trials!

DarshanTalks Podcast ·

2025/01/03

Subscriber-only episodeIn this episode, Darshan explores how artificial intelligence (AI) is transforming clinical trial design, with a focus on using real-world data (RWD). The episode dives into the FDA’s recognition of AI’s potential to enhance clinical trials by using data from electronic health records (EHRs), medical claims, and disease registries. AI’s ability to analyze large data sets enables identification of patterns that can predict chronic disease progression, leading to more per...

en-us

340 results

Similar Podcasts

Realitätstheorie

Benjamin Ewers, Raoul-Amadeus Lorbeer

Sci-Fi Books -Daily

solgoodmedia.com

New Books in Science

New Books Network

Science News Daily

brief.news

DarshanTalks Podcast

Darshan Kulkarni